Intravenous Infusion
This method allows for rapid delivery and absorption of substances into the bloodstream, making it a common and essential practice in healthcare settings.
Intravenous infusions are used to treat dehydration, deliver critical medications, provide nutrition, and support various medical conditions.
The process involves inserting a small catheter into a vein, typically in the arm or hand, and connecting it to a bag or bottle of the infusion solution.
The rate and volume of the infusion can be carefully controlled to meet the patient's specific needs.
Proper technique and monitoring are crucial to ensure the safety and efficacy of intravenous infusions and to prevent potential complications, such as infection, thrombosis, or fluid overload.
Reserach into optimal intravenous infusion protocols is an important area of study to enhance patient outcomes and reproducibilty of results.
Most cited protocols related to «Intravenous Infusion»
For G1, anatomic MRI images were acquired with T1-weighted magnetization-prepared rapid gradient echo (MPRAGE) sequence (1 mm isotropic voxels) variably using a Siemens Trio 3T scanner (N = 72), a Siemens Vision 1.5T (N = 3), or a Siemens Avanto 1.5 T scanner (N = 2). For G2, two MPRAGE scans were acquired during the same MR session for each participant on the Siemens Trio 3T scanner to investigate the impact of FreeSurfer segmentation variability on PET quantification.
Most recents protocols related to «Intravenous Infusion»
Example 8
Characterization of Absorption, Distribution, Metabolism, and Excretion of Oral [14C]Vorasidenib with Concomitant Intravenous Microdose Administration of [13C315N3]Vorasidenib in Humans
Metabolite profiling and identification of vorasidenib (AG-881) was performed in plasma, urine, and fecal samples collected from five healthy subjects after a single 50-mg (100 μCi) oral dose of [14C]AG-881 and concomitant intravenous microdose of [13C3 15N3]AG-881.
Plasma samples collected at selected time points from 0 through 336 hour postdose were pooled across subjects to generate 0—to 72 and 96-336-hour area under the concentration-time curve (AUC)-representative samples. Urine and feces samples were pooled by subject to generate individual urine and fecal pools. Plasma, urine, and feces samples were extracted, as appropriate, the extracts were profiled using high performance liquid chromatography (HPLC), and metabolites were identified by liquid chromatography-mass spectrometry (LC-MS and/or LC-MS/MS) analysis and by comparison of retention time with reference standards, when available.
Due to low radioactivity in samples, plasma metabolite profiling was performed by using accelerator mass spectrometry (AMS). In plasma, AG-881 was accounted for 66.24 and 29.47% of the total radioactivity in the pooled AUC0-72 h and AUC96-336 h plasma, respectively. The most abundant radioactive peak (P7; M458) represented 0.10 and 43.92% of total radioactivity for pooled AUC0-72 and AUC96-336 h plasma, respectively. All other radioactive peaks accounted for less than 6% of the total plasma radioactivity and were not identified.
The majority of the radioactivity recovered in feces was associated with unchanged AG-881 (55.5% of the dose), while no AG-881 was detected in urine. In comparison, metabolites in excreta accounted for approximately 18% of dose in feces and for approximately 4% of dose in urine. M515, M460-1, M499, M516/M460-2, and M472/M476 were the most abundant metabolites in feces, and each accounted for approximately 2 to 5% of the radioactive dose, while M266 was the most abundant metabolite identified in urine and accounted for a mean of 2.54% of the dose. The remaining radioactive components in urine and feces each accounted for <1% of the dose.
Overall, the data presented indicate [14C]AG-881 underwent moderate metabolism after a single oral dose of 50-mg (100 μCi) and was eliminated in humans via a combination of metabolism and excretion of unchanged parent. AG-881 metabolism involved the oxidation and conjugation with glutathione (GSH) by displacement of the chlorine at the chloropyridine moiety. Subsequent biotransformation of GSH intermediates resulted in elimination of both glutamic acid and glycine to form the cysteinyl conjugates (M515 and M499). The cysteinyl conjugates were further converted by a series of biotransformation reactions such as oxidation, S-dealkylation, S-methylation, S-oxidation, S-acetylation and N-dealkylation resulting in the formation multiple metabolites.
A summary of the metabolites observed is included in Table 2
Example 7
Use in Patients for Treating Solid Tumours
Stored haematopoietic cells (e.g. haematopoietic stem cells or granulocyte precursor cells obtainable therefrom), and granulocytes (e.g. neutrophils) differentiated therefrom are matched to cancer patients based on their cancer type, blood type (ABO, rhesus and HLA), and/or genetics. Patients may also be matched based on human leukocyte antigen (HLA) similarity.
Patients are treated using:
-
- IV infusion of haematopoietic cells (including haematopoietic stem cells, and granulocyte precursor cells) together with granulocyte-colony stimulating factor, human growth hormone, serotonin, and interleukin into the patient; or
- IV infusion of stimulated granulocyte precursor cells (obtainable from haematopoietic stem cells) into the patient. Without wishing to be bound by theory, it is believed that said cells naturally differentiate into granulocytes (e.g. neutrophils) having a high CKA in a CKA assay in vivo; or
- direct IV infusion of granulocytes (e.g. neutrophils) having a high CKA in a CKA assay which have been differentiated from haematopoietic cells (e.g. haematopoietic stem cells).
Typically, cells are infused once weekly for 8 weeks with a cell volume of 2×1011 administered per week. Progress of the therapy is monitored and dosing is adapted accordingly.
Example 20
Materials and Methods
B cell activation of the cynoCEA×CD40 RUBY™ (AC_05355) on cynomolgus and human B cells in the presence of CEA transfected cells (macaque CEA, NP_001040590.1). Primary cynomolgus B cells were cultured with titrated antibodies in the presence CEA expressed on CHO cells. After 2 days, expression of CD86 on B cells was analyzed by FACS.
The cynoCEA×CD40 bispecific antibody (AC_05355) was administered once weekly via intravenous infusion for 2 weeks to cynomolgus monkeys at two different dose levels (10 mg/kg and 37.5 mg/kg). One female and one male were evaluated at each dose level.
Results
Example 1
The Expression of human GPRC5D was evaluated in various malignant and normal tissues by investigating gene expression profiles in databases such as the cancer cell line encyclopedia and BioGPS. As shown in
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Top products related to «Intravenous Infusion»
More about "Intravenous Infusion"
Explore the latest advancements in IV therapy, including rapid delivery of fluids, medications, and nutrition directly into the bloodstream.
Discover best practices for preventing complications like infection, thrombosis, and fluid overload.
Leverage AI-driven platforms to identify the most effective IV protocols from literature, pre-prints, and patents.
Enhance research accuracy and reproducibility with smart comparisons of IV infusion methods.
Gain insights from leading imaging technologies like Magnevist, Gadovist, Magnetom Avanto, Dotarem, Biograph mCT, Achieva, Ingenia, Ultravist 370, and LightSpeed VCT to optimize IV infusion for optimal patient outcomes.
Uncover the latest SOMATOM Definition Flash advancements in IV infusion monitoring and control.
Mastering intravenous (IV) infusion is a critical skill in healthcare, enabling rapid delivery of essential fluids, medications, and nutrients directly into the patient's veins.
This method allows for quick absorption and distribution throughout the body, making it a common and indispensable practice in medical settings.
IV infusions are used to treat dehydration, deliver critical therapies, provide parenteral nutrition, and support a wide range of medical conditions.
The process involves inserting a small catheter into a vein, typically in the arm or hand, and connecting it to a bag or bottle of the infusion solution.
Careful control over the rate and volume of the infusion is crucial to meet the patient's specific needs and prevent potential complications.
Reserach into optimal IV infusion protocols is an important area of study, as it can enhance patient outcomes and ensure the reproducibility of research results.
By leveraging the power of AI-driven platforms, healthcare professionals can identify the best infusion methods from a wealth of literature, pre-prints, and patents, enabling them to deliver the most effective IV therapies and improve the accuracy and consistency of their research findings.